Dr Reddy's Semaglutide Delay Sparks Brokerage Divide; Kotak Calls It 'Another Dose Of Disappointment' — Check Target

Brokerages have retained their ratings but highlighted concerns over the delay in semaglutide commercialisation following an API impurity issue disclosed by the company during its earnings call.